Figma Shares Indicated To Open $105/$110
Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), recently sold shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The sale comes as the stock has declined 26.56% over the past week, according to InvestingPro data. On March 17 and 18, Ma disposed of a total of 2,242 shares, generating proceeds of approximately $26,658. The shares were sold at prices ranging from $10.24 to $12.09 per share. Following these transactions, Ma retains ownership of 2,829,018 shares, held indirectly by a spouse. These sales were conducted under a pre-established Rule 10b5-1 trading plan. The company maintains strong financial health with a current ratio of 3.32 and impressive gross margins of 96.33%. Want deeper insights into insider trading patterns and 10+ additional exclusive ProTips? Check out InvestingPro.
In other recent news, Gyre Therapeutics reported fourth-quarter revenue of $27.87 million, reflecting a slight increase from $27.1 million in the same period the previous year. The company’s full-year 2025 revenue guidance, projected between $118 million and $128 million, fell short of analyst expectations, which had anticipated $135.7 million. This guidance assumes the launch of two new products: nintedanib for idiopathic pulmonary fibrosis and avatrombopag for chronic liver disease-associated thrombocytopenia. Gyre plans to introduce these drugs in China this year, complementing its existing ETUARY (pirfenidone) franchise. Despite the lower-than-expected guidance, the company highlighted an 11.3% to 20.8% growth over 2024. ETUARY sales saw a year-over-year increase of $1 million, although this was partially offset by a decline in generic drug revenue. CEO Han Ying expressed confidence in the company’s ability to launch and expand its new products, citing a proven track record and robust sales and marketing platform. Gyre concluded 2024 with $51.2 million in cash and investments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.